The ECOG tissue banks are a critical part of ECOG's translational science program, providing a valuable resource to investigators at both ECOG member and non-member institutions. This application proposes continued support for the coordination and operation of these banks with the goal of collecting, processing, and storing high-quality specimens and making them available to investigators for use in approved correlative science projects. ECOG will increase the marketing of its high quality banked specimens for use in cutting edge research which in turn will change clinical care. ECOG is an active participant in the NCI-Clinical Trials Cooperative Groups'Group Banking Committee (GBC) and is committed to working with the GBC, through ECOG representation on the Steering Committee and subcommittees, toward the common goal of a harmonized system for the collection, processing, storage, and distribution of specimens across all Cooperative Group Banks. The use of common techniques ensures that samples are of sufficient quality for use in cutting edge research, facilitates pooling specimens from multiple banks for large scale translational projects, and enhances the ability to compare results across projects. Common vocabularies and data structures, as well as common policies for specimen requests, make the system easier to navigate for ail investigators regardless of cooperative group membership status. This creates a collegial, robust and productive cancer research system. The three main ECOG specimen banks are the Solid Tumor Bank (the ECOG PCO-RL), the Leukemia Tissue Bank, and the Myeloma Tissue Bank. Each collects and banks well annotated specimens from Cooperative Group clinical trials according to strict SOPs based on recommended Best Practices and follows GBC practices to make them available to investigators.

Public Health Relevance

Banked biospecimens from large cooperative group trials, with clinical annotation and linked follow-up data, can be used for many research projects. The most important projects are those which identify or validate biomarkers;genes or proteins which can be used to predict responses to treatment. The well annotated specimens in the ECOG banks can thus be used to further the mission of individualized therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA114737-08
Application #
8534451
Study Section
Special Emphasis Panel (ZCA1-SRLB-5 (M1))
Program Officer
Ganguly, Aniruddha
Project Start
2005-08-19
Project End
2014-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
8
Fiscal Year
2013
Total Cost
$573,005
Indirect Cost
$11,733
Name
Frontier Sci & Technology Rsch Fdn, Inc
Department
Type
DUNS #
080330186
City
Boston
State
MA
Country
United States
Zip Code
02215
Vu, Ly P; Prieto, Camila; Amin, Elianna M et al. (2017) Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat Genet 49:866-875
Gu, Zhaohui; Churchman, Michelle; Roberts, Kathryn et al. (2016) Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun 7:13331
Iacobucci, Ilaria; Li, Yongjin; Roberts, Kathryn G et al. (2016) Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell 29:186-200
Cesano, Alessandra; Willman, Cheryl L; Kopecky, Kenneth J et al. (2015) Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia. PLoS One 10:e0118485
Wagner, Lynne I; Zhao, Fengmin; Hong, Fangxin et al. (2015) Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). J Clin Oncol 33:740-8
Okoye-Okafor, Ujunwa C; Bartholdy, Boris; Cartier, Jessy et al. (2015) New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nat Chem Biol 11:878-86
Chen, L; Chen, W; Mysliwski, M et al. (2015) Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. Leukemia 29:1290-300
Chen, Zhengshan; Shojaee, Seyedmehdi; Buchner, Maike et al. (2015) Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature 521:357-61
Buchner, Maike; Park, Eugene; Geng, Huimin et al. (2015) Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. Nat Commun 6:6471
Churchman, Michelle L; Low, Jonathan; Qu, Chunxu et al. (2015) Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. Cancer Cell 28:343-56

Showing the most recent 10 out of 165 publications